TY - JOUR
T1 - Global cost modeling analysis of HIV-1 and HCV viral load assays
AU - Elbeik, Tarek
AU - Dalessandro, Ralph
AU - Chen, Yi Ming Arthur
AU - Soutchkov, Serguei V.
AU - Loftus, Richard A.
AU - Beringer, Scott
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - This review addresses hidden costs associated with the Bayer VERSANT® assay, Roche AMPLICOR MONITOR® test and COBAS AMPLICOR MONITOR® test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effective approach for these tests is presented. The analyses demonstrate the need for manufacturers to consider labor and supply costs when marketing a kit in resource-poor countries, noting that marketing strategies need to change. In the absence of any proven monitoring alternative, emphasis is placed on increasing market share to promote significant reduction in kit prices to suit the demands of markets in resource-poor countries. Finally, recommendations are made to improve the overall cost structure of viral load testing. This review is intended as a tool to optimize assay usage in attaining the lowest performance costs by assay and is not to endorse any test, as will become apparent.
AB - This review addresses hidden costs associated with the Bayer VERSANT® assay, Roche AMPLICOR MONITOR® test and COBAS AMPLICOR MONITOR® test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effective approach for these tests is presented. The analyses demonstrate the need for manufacturers to consider labor and supply costs when marketing a kit in resource-poor countries, noting that marketing strategies need to change. In the absence of any proven monitoring alternative, emphasis is placed on increasing market share to promote significant reduction in kit prices to suit the demands of markets in resource-poor countries. Finally, recommendations are made to improve the overall cost structure of viral load testing. This review is intended as a tool to optimize assay usage in attaining the lowest performance costs by assay and is not to endorse any test, as will become apparent.
KW - Bayer VERSANT bDNA
KW - Center of excellence
KW - COBAS
KW - Cost model
KW - Examples
KW - HCV
KW - HIV-1
KW - Labor and supply costs
KW - Resource-poor countries
KW - Resource-rich countries
KW - Roche AMPLICOR MONITOR
UR - https://www.scopus.com/pages/publications/0041560004
UR - https://www.scopus.com/pages/publications/0041560004#tab=citedBy
U2 - 10.1586/14737167.3.4.383
DO - 10.1586/14737167.3.4.383
M3 - Review article
AN - SCOPUS:0041560004
SN - 1473-7167
VL - 3
SP - 383
EP - 407
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 4
ER -